| Bioactivity | Tengonermin (ARENEGYR) is a vascular-targeting agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. Tengonermin increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment[1][2]. |
| Invitro | NGR-hTNF 是一种实体瘤抑制剂，通过 NGR 基序特异性靶向血管生成肿瘤血管[1]。 |
| Name | Tengonermin |
| CAS | 1960461-99-7 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Valentinis B, et, al. Mechanism of Action of the Tumor Vessel Targeting Agent NGR-hTNF: Role of Both NGR Peptide and hTNF in Cell Binding and Signaling. Int J Mol Sci. 2019 Sep 12;20(18):4511. [2]. Gregorc V, et, al. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2018 Jun;19(6):799-811. |